Sun Pharmaceutical Industries Limited recently announced the introduction of Tedizolid Phosphate tablets 200 mg in India under the brand name “STARIZO”. STARIZO (Tedizolid Phosphate) is a new oxazolidinone-class antibiotic used to treat Acute Bacterial Skin and Skin Structure Infections (ABSSI).
The company has acquired rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India.
Kirti Ganorkar, CEO – India Business, Sun Pharma said, “Drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) causing ABSSSIs, are more challenging to treat due to the limited availability of effective treatment options in hospitals.[i] With STARIZO, we are introducing a treatment option which is effective and has the convenience of once-a-day dosing. At Sun Pharma, it has always been our endeavour to introduce innovative medicines that help improve the quality of life of patients.”
In the meantime, as of 2:27 pm, Sun Pharmaceutical shares were trading 1.63% higher at Rs 1,779.20 on the NSE.
